Phase III Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis

In this ongoing phase III, multicenter, randomized, double-blind, placebo-controlled trial, investigators assigned 1197 patients with biopsy-defined metabolic dysfunction–associated steatohepatitis and fibrosis stage 2 or 3 in a 2:1 ratio to receive once-weekly subcutaneous semaglutide at a dose of 2.4 mg or placebo for 240 weeks.